首页> 外文期刊>Clinical oral investigations >Effect of oral appliance on circulating leukocyte telomere length and SIRT1 in obstructive sleep apnea
【24h】

Effect of oral appliance on circulating leukocyte telomere length and SIRT1 in obstructive sleep apnea

机译:口服用具对阻塞性睡眠呼吸暂停循环白细胞端粒长度和SIRT1的影响

获取原文
获取原文并翻译 | 示例
           

摘要

ObjectivesThe increased cardiovascular risk seen in patients with obstructive sleep apnea (OSA) may be due to combination of oxidative stress, systemic inflammation and damage to leukocyte telomere length (LTL) seen with aging. Another molecule, Sirtuin 1 (SIRT1), a histone/protein deacetylase, regulates endothelial nitric oxide synthase and is involved in different aspects of cardiovascular disease, aging and stress resistance. The aim of this study was to evaluate the effects of mandibular advancement device (MAD) on the circulating LTL and SIRT1 protein level in peripheral blood mononuclear cells (PBMCs) in patients with OSA.Materials and methodsForty patients with moderately severe to severe OSA who desired MAD and 20 healthy controls were prospectively enrolled. The LTL was measured by quantitative polymerase chain reaction while SIRT1 protein levels in PBMC was assessed using a Sirtuin 1 ELISA Kit. All study subjects underwent baseline sleep study, with OSA patients having repeat testing at 3months after MAD.ResultsCompared to healthy subjects, patients with OSA at baseline had lower LTL and SIRT1 protein levels in PBMC. After 3months of MAD, 24 OSA patients, designated as MAD responders, median (range) LTL increased from (0.556 [0.393-0.748]) to (0.708 [0.533-0.893]) and SIRT1 protein levels in PBMC increased from 0.580.23pg/g of total protein to 0.950.26pg/g of total protein. For the 16 MAD unresponsive patients, LTL and SIRT1 protein levels remained low.Conclusionsp id=Par4Successful treatment of OSA with MAD can restore LTL and SIRT1 protein levels in PBMC.Clinical relevancep id=Par5LTL and SIRT1 protein levels in PBMC can be improved following effective treatment of OSA using MAD.
机译:对象患者在阻塞性睡眠呼吸暂停(OSA)患者中可以增加心血管风险可能是由于氧化应激,全身炎症和随老化的白细胞端粒长度(LT1)的损伤的组合。另一种分子,Sirtuin 1(Sirt1),组蛋白/蛋白质脱乙酰化酶调节内皮一氧化氮合酶,并且参与心血管疾病,老化和胁迫性的不同方面。本研究的目的是评估下颌推进装置(MAD)对OSA的患者外周血单核细胞(PBMC)中的循环LTL和SIRT1蛋白水平的影响.MARTIALS和MethodureSforty患者中度严重至严重的OSA所需的严重OSA疯狂和20个健康的对照,并进行了初步注册。通过定量聚合酶链反应测量LT1,而使用SIRTUIN 1 ELISA试剂盒评估PBMC中的SIRT1蛋白水平。所有研究受试者接受了基线睡眠研究,OSA患者在疯狂后3个月重复测试。对健康受试者的3个月,基线OSA的患者在PBMC中具有较低的LTL和SIRT1蛋白水平。在3个疯狂的24名OSA患者之后,指定为MAD响应者,中位数(范围)LTL从(0.556 [0.393-0.748])增加到(0.708 [0.533-0.893])和PBMC中的SIRT1蛋白水平从0.580.23pg增加/ G总蛋白质至0.950.26pg / g的总蛋白质。对于16名疯狂的无响应患者,LTL和SIRT1蛋白质水平仍然很低。CONCLUSIONSP ID = PAR4CACCESFESFE治疗OSA的OSA可以恢复PBMC中的LTL和SIRT1蛋白水平。临床相关性PABMC中的PBMC中的PAR5LT1和SIRT1蛋白水平可以改善使用MAD治疗OSA。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号